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Abstract
With the increasing incidence of coronary artery disease, the percutaneous 
coronary intervention (PCI) has become one of the most effective treatments for 
coronary artery disease. After more than 40 years of clinical application, develop-
ment and research, and continuous improvement, it has been widely used around 
the world. In recent years, due to the continuous innovation of drug-eluting stents, 
equipment, drugs, and interventional technology, the indications for treatment 
have been continuously broadened, many heart centers can deal with complete 
revascularization for high-risk indicated patient session, and the efficacy has been 
further improved. However, studies have shown that there are gender differences 
in the clinical prognosis of patients with coronary artery disease after percutaneous 
coronary intervention, which are affected by many related risk factors of gender 
differences, but there is lack of systematic and comprehensive review of relevant 
factors. The purpose of this review is to evaluate the possible causes of gender dif-
ferences in the clinical outcomes of patients after percutaneous coronary interven-
tion and to put forward recommendations for primary prevention and secondary 
prevention.
Keywords: coronary artery disease, percutaneous coronary intervention, gender, 
differences
1. Introduction
Coronary artery disease is the most common cardiovascular disease caused by 
myocardial ischemia, hypoxia, and necrosis due to coronary stenosis, spasm, or 
occlusion. Since the first application of percutaneous coronary intervention (PCI) 
to myocardial infarction by Gruentzig in 1977, it has become the most common 
method to recover myocardial reperfusion under various states, significantly 
improving the survival and quality of life of patients with coronary artery disease 
[1]. Notably, PCI has been considered as the cornerstone of management for 
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patients with or without ST elevation acute coronary syndromes [2–4]. In the past 
two decades, with the emergence of drug-eluting stent, the indication of PCI in 
high-risk patients with coronary artery disease has been tremendously broadened. 
In recent years, the progress of interventional techniques has also fundamen-
tally changed the treatment of coronary artery disease. Moreover, since balloon 
angioplasty has been used in patients with coronary artery disease, the influence 
of gender on clinical outcomes after PCI has been continuously investigated. In 
particular, previous studies have reported that the incidence of adverse outcomes 
in female patients with coronary artery disease after PCI is higher than that in male 
patients with those after PCI, including short- and long-term mortality, major 
adverse cardiovascular events (MACE), and revascularization. On the one hand, 
some studies have shown that gender differences in clinical outcomes persist after 
adjusting for multivariate factors, such as age, prior peripheral vascular disease, 
prior myocardial infarction, prior PCI, and chronic renal failure [5–8]. On the other 
hand, other studies have demonstrated that gender is not an independent factor 
in the clinical outcome [9–11]. Due to the protection of estrogen, a large number 
of studies have revealed that the onset age of female patients with coronary artery 
disease is approximately 5–10 years later than that of male patients with those. 
Additionally, the prevalence of hypertension, diabetes mellitus, and hyperlipidemia 
was higher in female individual than that in male individual, while the prevalence 
of former or current smokers was more in male individual. Therefore, the purpose 
of the present review is to summarize the gender differences in clinical studies of 
patients with coronary artery disease after PCI and to put forward suggestions for 
improving primary and secondary prevention strategies.
2. Representative researches
In a Japanese observational study including 43,231 patients with non-ST-
segment elevation acute coronary syndrome who underwent PCI from January 2014 
to December 2014, the authors concluded that female patients had a higher risk of 
hospital complications than male patients, especially bleeding [5]. Another large-
scale cohort study involving 95,030 male and 35,955 female patients from a clinical 
registry of PCI procedures revealed that female gender remained as an independent 
predictor for mortality of patients with coronary artery disease underwent PCI 
after multivariable adjustment from January 2006 to February 2011[6]. A multi-
center study from the United Kingdom and Sweden, which included 338,462 male 
and 119,799 female patients, indicated that female patients with coronary artery 
disease after PCI had a higher all-cause mortality than male patients with those 
and the age was also a strong predictor of mortality [7]. Moreover, a retrospective 
cohort study from Germany showed that female patients with ST-segment elevation 
myocardial infarction undergoing PCI harbored a 20% higher age-adjusted risk of 
death and ischemic cardiac and cerebrovascular events [8].
A systematic review involving 21 studies with 21,666 patients from the 
Netherlands showed that crude short- and long-term mortality was higher in female 
patients with ST-segment elevation myocardial infarction than that in male patients 
with those. However, the abovementioned gender differences generally disappeared 
after adjusting for baseline characteristics [12]. A comprehensive meta-analysis 
from the United States reported that there were gender differences in patients with 
coronary artery disease who underwent PCI, including short- and long-term mor-
tality. Nevertheless, these differences were also gradually weakened after adjusting 
for the clinical differences and/or hospitalization course [13]. Although there were 
no significant gender differences in long-term mortality after adjustment, the 
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short-term mortality of female patients with coronary artery disease undergo-
ing primary angioplasty was still higher than that of male patients with those. 
Meanwhile, a meta-analysis involving 48 studies from Italy to explore the gender 
differences in clinical outcomes for patients with ST-segment elevation myocardial 
infarction who underwent PCI [14] indicated that female patients with ST-segment 
elevation myocardial infarction undergoing PCI had higher rates of bleeding and 
stroke and the early mortality was lower than that of male patients with those, but 
not in the mid-term.
Both previous qualitative and quantitative studies have suggested that there are 
gender differences in clinical outcomes of patients with coronary artery disease 
after PCI, which are mainly reflected in the fact that the mortality rate of female 
patients with those is higher than that of male patients with those; however, the 
above systematic review and meta-analysis results were only limited to patients 
with ST-segment elevation myocardial infarction who underwent PCI. In order to 
determine the prognosis other than mortality, a systematic review was performed, 
which suggested that the prognosis of male patients with coronary artery disease 
after PCI was better than that of female patients with those, including mortality, 
MACE, and short-term revascularization, except for long-term revascularization 
[15]. Based on the results of previous studies, it is necessary to analyze the possible 
causes of these gender differences.
3. Related factors of gender differences
3.1 Risk factors
It is clear that the elderly patients not only have a higher risk of cardiovas-
cular disease but also have a higher risk of mortality. The major reason for the 
delayed onset of female patients with coronary artery disease is the protective 
effect of estrogen, which can be delayed to female patients with postmenopause. 
Estrogen can directly protect myocardial cells, reduce myocardial apoptosis, 
and prevent plaque rupture through sarcKATP channels and β-estrogen recep-
tor [16, 17]. Nevertheless, female patients with coronary artery disease were 
facing the same risk factors as male patients with those. Female patients with 
coronary artery disease frequently had hypertension in clinical practice, which 
can damage endothelial cells, lead to endothelial dysfunction, and accelerate 
atherosclerosis. Meanwhile, hypertension is associated with chronic alterations 
of renin-angiotensin-aldosterone system and overexpression of angiotensin II 
receptor 1/renin-angiotensin-aldosterone system, which can increase myocardial 
fibrosis, cardiomegaly, extracellular matrix, and diastolic dysfunction. Besides, 
elevated blood pressure can also increase infarct size of patients with myocar-
dial infarction [18]. In addition, previous studies have shown that more female 
patients with cardiovascular disease had diabetes mellitus and dyslipidemia, 
which can impair the endothelial cells of coronary artery and strengthen the 
functions of coagulation factor VIII and platelets, which can thereby further 
accelerate the occlusion of the coronary artery and arteriosclerosis. It has been 
shown that hyperuricemia and hyperhomocysteinemia are independent predic-
tors of female patients with coronary artery disease. Uric acid crystals can deposit 
on the vessel wall, which can promote inflammation and atherosclerosis [19]. 
Hyperhomocysteinemia can affect the functions of vascular endothelial cells and 
lipid metabolism and increase platelet aggregation and adhesion [20, 21]. All of 
these risk factors may contribute to the occurrence of adverse prognosis events in 
female patients with coronary artery disease after PCI.
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3.2 Anatomy and pathophysiology
Some studies have elucidated that gender differences in the prognosis of 
patients with coronary artery disease after PCI are due to the fundamental dif-
ferences in physiology, pathophysiology, pathological anatomy, and other aspects 
between male and female. Anatomically, the coronary arteries of female patients 
with coronary artery disease are smaller than that of male patients with those, 
and the smaller blood vessels can cause higher risks of bleeding complications 
and vascular damage [22]. In general, male patients with coronary artery disease 
are prone to complex lesions, such as left main artery lesions, chronic total occlu-
sion lesions, and long lesions, while female patients with coronary artery disease 
tend to have small vessel lesions, which are more likely to show no significant 
stenosis of the coronary artery during coronary angiography [23]. Meanwhile, 
coronary microvascular reactivity and myocardial response to ischemia are also 
different between male and female individuals. It is suggested that the hemo-
dynamic state of female patients with coronary artery disease is worse than that 
of male patients with those, which leads to differences of cell cycle process and 
apoptosis-related protein levels of cardiac fibroblasts between different genders 
[24]. In addition, female patients with myocardial infarction often show atypi-
cal symptoms [25]. As a result, such patients will not be paid much attention to, 
and physicians may be misled or underestimate the possibility of acute coronary 
syndrome, thereby prolonging the time from myocardial infarction to revascu-
larization [26]. These pathophysiology and anatomy differences are irreversible 
factors. If the physiological and pathological characteristics of female patients 
with coronary artery disease can be identified in time, appropriate coronary 
intervention strategies will be selected to reduce complications and improve their 
clinical prognosis.
3.3 Ischemia-reperfusion time
According to the statistics of the time from the onset of coronary artery 
disease to reperfusion ischemia time, the interval of female patients was longer 
than that of male patients, including the prehospital delay and the time from door 
to balloon [27–30]. A study by Lichtman et al. has revealed that the cardiovascular 
risk of female patients with coronary artery disease, especially young female 
patients with those, is not easy to be accurately assessed, which may lead to be 
delayed diagnosis of acute myocardial infarction, thereby affecting treatment and 
prognosis [31]. Another registration study from one of 11 centers in Switzerland 
providing primary PCI around the clock, which has demonstrated that female 
patients with acute myocardial infarction between 2005 and 2010 may be dis-
criminated when they receive PCI [32]. It is speculated that this situation may also 
exist in other countries. The prognosis of female patients with coronary artery 
disease who are discriminated in clinic is partly poor. Moreover, a study from the 
United States has found that female patients with coronary artery disease were 
less likely to undergo PCI than male patients with those and more female patients 
with those had delayed time of ischemia-reperfusion [33]. These controllable 
factors can lead to the failure of female patients with coronary artery disease to 
improve myocardial ischemia effectively in a short period of time, which is one 
of the important factors of poor prognosis. The duration of ischemia-reperfusion 
may be longer in female patients with these atypical symptoms than in male 
patients, which is another factor of higher mortality and MACE in female patients 
with coronary artery disease after PCI.
5Gender Differences in Clinical Outcomes of Patients with Coronary Artery Disease…
DOI: http://dx.doi.org/10.5772/intechopen.91878
3.4 MACE
MACE is one of the factors that significantly affect the prognosis for patients 
with coronary artery disease after PCI. Previous study has indicated that the 
incidence of MACE is lower in male patients with coronary artery disease after PCI 
than that in female patients with those [9, 10, 23, 34]. A prospective, multicenter, 
cohort study by Glaser et al. has exhibited that female patients with non-ST-seg-
ment elevation acute coronary syndrome undergoing PCI at the age of 65 was more 
likely to have MACE than male patients with those at the same time [28]. Further 
analysis has shown that the incidence of congestive heart failure was higher in 
female patients with ST-segment elevation myocardial infarction than that in male 
patients with those, and the former was more likely to have cardiogenic shock when 
myocardial infarction occurred [5–7]. High incidence of ventricular septal rupture 
and severe mitral regurgitation during cardiogenic shock can be considered as 
important factors affecting the poor prognosis of female patients with myocardial 
infarction in the hospital. In a word, the above pathological factors can lead to the 
high incidence of MACE in female patients with coronary artery disease after PCI.
3.5 Revascularization
A study has demonstrated that the low incidence of revascularization in 
female patients with coronary artery disease may also be attributed to the lower 
follow-up rate, atypical symptoms, difficulty identifying myocardial ischemia, 
unwillingness to undergo invasive investigations, and prejudice against female 
patients [9]. In addition, the mortality of female patients with coronary artery 
disease was higher during the short- and long-term follow-up compared with 
male patients with those, which may also reduce the chance of revascularization 
[23, 34]. Furthermore, male patients with coronary artery disease who underwent 
PCI often have more complex lesions, which may be also an independent predictor 
of revascularization [23]. In terms of pathophysiology, the male subjects are more 
likely to have atherosclerotic plaque rupture, platelet-rich thrombus, and micro-
embolism [35], while the platelets are more sensitive to aggregation stimulation 
in female patients, and this pathophysiological difference may also increase the 
risk of male patients with coronary artery disease who underwent PCI or CABG 
[36]. Moreover, some studies have shown that male patients with coronary artery 
disease have a higher PCI or CABG history than the female with those, which may 
be another reason for the higher incidence of overall revascularization in male 
patients with those [7, 8].
3.6 Other risk factors
Earlier evidence has supported that the female individuals would experience 
depression after the initial diagnosis of coronary artery disease and acute cardiac 
events, leading to all-cause mortality and the risk of MACE in the following months 
[37, 38]. Breast cancer is one of the most important causes of female individual 
death worldwide. However, the administration of estrogen receptor modulators in 
anti-breast cancer treatments may increase the incidence of coronary artery disease 
[39]. The incidence of autoimmune diseases for female individuals is also high, 
especially systemic lupus erythematosus, which is more common in female individ-
uals. The pathogenic antibodies of the disease can cause antiphospholipid antibody 
syndrome (thrombosis, thrombocytopenia), thereby involving coronary artery 
and even resulting in acute myocardial infarction [40]. Therefore, it is important 
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to prevent and reduce the incidence of female high-risk diseases and to reduce the 
mortality and MACE of female patients with coronary artery disease after PCI.
4. Primary and secondary prevention
For population with high risk of cardiovascular events in the future and popula-
tion who have already suffered from coronary artery disease, it is very important 
to implement the primary and secondary prevention of coronary artery disease. At 
present, various academic institutions around the world have formulated relevant 
suggestions, scientific statements, expert consensus documents, and clinical 
practice guidelines and put forward many measures for the primary and second-
ary prevention for patients with coronary artery disease and its PCI. However, the 
latest study shows that there are still significant gender differences for the primary 
and secondary prevention of cardiovascular disease. Compared with male patients, 
female patients with high risk of cardiovascular disease in the next 10 years are 
difficult to control their blood pressure, blood lipid, and body weight, while female 
patients who suffered from cardiovascular disease were worse in taking guideline-
directed medications [41]. Therefore, the secondary prevention is particularly 
important for patients with coronary artery disease after PCI. On the basis of adher-
ence to long-term drug treatment, the risk factors should be managed and con-
trolled, and appropriate exercise should be performed, especially female coronary 
artery disease patients with higher risk factors and poor prognosis after PCI.
5. Conclusions
PCI has long been the main treatment method for patients with coronary artery 
disease, which significantly reduces the mortality of myocardial infarction and 
improves the quality of life of patients. However, compared with male patients 
with coronary artery disease, female patients with those have a higher MACE and 
mortality after PCI, while male patients with those have advantages in revascular-
ization. Hypertension, diabetes mellitus, and dyslipidemia are the traditional risk 
factors of arteriosclerosis disease, which seriously affect the occurrence and devel-
opment of coronary artery disease. Female patients with coronary artery disease 
are faced with more cardiovascular risk factors and adverse factors affecting the 
prognosis of PCI, which is a major challenge for female patients with PCI. In addi-
tion, it is necessary to pay attention to the management of non-cardiovascular risk 
factors for postmenopausal female. Meanwhile, psychological diseases should be 
identified and intervened in patients with coronary artery disease in time. Finally, it 
should be emphasized that the prevention and treatment of coronary artery disease 
should not be ignored for individuals with more than 65 years and population with 
vulnerable region of medical resources.
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